fingolimod grindeks 0,5 mg cietās kapsulas
grindeks, as, latvia - fingolimods - kapsula, cietā - 0,5 mg
fingolimod zentiva 0,5 mg cietās kapsulas
zentiva, k.s., czech republic - fingolimods - kapsula, cietā - 0,5 mg
fingolimod medochemie 0,5 mg cietās kapsulas
medochemie ltd., cyprus - fingolimods - kapsula, cietā - 0,5 mg
fingolimod teva 0,5 mg cietās kapsulas
teva gmbh, germany - fingolimods - kapsula, cietā - 0,5 mg
efigalo 0,5 mg cietās kapsulas
krka, d.d., novo mesto, slovenia - fingolimods - kapsula, cietā - 0,5 mg
inzolfi 0,5 mg cietās kapsulas
sandoz pharmaceuticals d.d., slovenia - fingolimods - kapsula, cietā - 0,5 mg
fingolimod stada 0,5 mg cietās kapsulas
stada arzneimittel ag, germany - fingolimods - kapsula, cietā - 0,5 mg
inzolfi 0,25 mg cietās kapsulas
sandoz d.d., slovenia - fingolimods - kapsula, cietā - 0,25 mg
bonaxon 0,5 mg cietās kapsulas
egis pharmaceuticals plc, hungary - fingolimods - kapsula, cietā - 0,5 mg
tyruko
sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imūnsupresanti - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 un 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.